West Wireless Names CEO, Amylin Pharmaceuticals Awaits FDA Deadline, Life Technologies In Cancer Research Partnership, & More San Diego Life Sciences News
(Page 2 of 2)
gene sequencing instruments and lab supplies, is joining with two partners—the Phoenix-based Translational Genomics Research Institute and U.S. Oncology in Woodands, TX—to sequence the genomes of 14 women with an aggressive form of breast cancer.
—Neurocrine Biosciences (NASDAQ: NBIX), the San Diego biotech company developing treatments for neurological and endocrine disorders, raised gross proceeds of about $20 million in a stock offering.
—Amylin Pharmaceuticals (NASDAQ: [ticker:AMLN]]) and partners Waltham, MA-based Alkermes (NASDAQ: ALKS) and Eli Lilly (NYSE: LLY) are awaiting the March 12 deadline for an FDA decision on their application to market a once-weekly version of the diabetes drug exenatide (Byetta).
—Acadia Pharmaceuticals (NASDAQ: ACAD) and partner Biovail (NYSE: BVF), a Canadian biotech, provided an update on the development plans for the experimental drug pimavanserin.
—Cardium Therapeutics (NYSE Amex: CXM) raised $5 million from institutional investors in a direct offering, according to a press release.
Trending on Xconomy
Enjoy this? Please share it.
Denise Gellene is a former Los Angeles Times science writer and regular contributor to Xconomy. You can reach her at email@example.com